Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial

David M. Gershenson*, Austin Miller, William E Brady, James Paul, Karen Carty, William Rodgers, David Millan, Robert L Coleman, Kathleen N Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M O'Malley, Oliver Dorigo, Stephanie Gaillard, Hani Gabra, Brian Slomovitz, Parviz Hanjani, John Farley, Michael ChurchmanAilith Ewing, Robb Hollis, C Simon Herrington, Helen Q Huang, Lari B Wenzel, Charlie Gourley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalThe Lancet
Early online date4 Feb 2022
DOIs
Publication statusPublished - 5 Feb 2022

Cite this